Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bone ; 145: 115842, 2021 04.
Article in English | MEDLINE | ID: mdl-33422700

ABSTRACT

OBJECTIVES: This study aimed to evaluate the involvement of Angiotensin II (Ang II) in joint lesions associated with osteoarthritis (OA) in vitro and in vivo. METHODS: Chondrocyte cultures were obtained from knee joints of neonatal rats and stimulated with Ang II/MIA/ACE inhibitors. In vivo, rats treated or not with the ACE inhibitor captopril, received daily injections of Ang II or sodium monoiodoacetate (MIA) in knee joints for evaluation of cartilage, bone, and synovial lesions. RESULTS: Cultured chondrocytes expressed the mRNA for Ace, Agtr1, Agtr2, and Mas1. Stimulating cells with Ang II reduced chondrocyte viability and metabolism. Accordingly, in vivo Ang II injection into the knees of rats triggered hyperalgesia, joint edema, increased the number of leukocytes in the joint cavity, and induced cartilage lesions associated with OA alterations. In further experiments, Ang II synthesis was prevented with the ACE inhibitor Captopril in the context of MIA-induced OA. Ang II inhibition with captopril improved the OARSI score, induced chondroprotection, and reduced the leukocyte recruitment from synovium after MIA. Additionally, captopril prevented MIA-induced bone resorption, by decreasing the number of osteoclasts and increasing the expression of IL-10 in the bone. In vitro, inhibiting Ang II synthesis decreased MIA-induced chondrocyte death and increased Col2a1 transcription. CONCLUSION: Ang II induces chondrocyte death and joint tissue damages associated with OA and its modulation can be a therapeutic strategy in osteoarthritis.


Subject(s)
Cartilage, Articular , Osteoarthritis, Knee , Osteoarthritis , Angiotensin II , Animals , Chondrocytes , Knee Joint , Osteoarthritis/drug therapy , Osteoarthritis, Knee/drug therapy , Proto-Oncogene Mas , Rats
2.
Materials (Basel) ; 12(16)2019 Aug 16.
Article in English | MEDLINE | ID: mdl-31426290

ABSTRACT

Hydroxyapatite and bioactive glass particles were added to pure magnesium and an AZ91 magnesium alloy and then consolidated into disc-shaped samples at room temperature using high-pressure torsion (HPT). The bioactive particles appeared well-dispersed in the metal matrix after multiple turns of HPT. Full consolidation was attained using pure magnesium, but the center of the AZ91 disc failed to fully consolidate even after 50 turns. The magnesium-hydroxyapatite composite displayed an ultimate tensile strength above 150 MPa, high cell viability, and a decreasing rate of corrosion during immersion in Hank's solution. The composites produced with bioactive glass particles exhibited the formation of calcium phosphate after 2 h of immersion in Hank's solution and there was rapid corrosion in these materials.

SELECTION OF CITATIONS
SEARCH DETAIL
...